Cytokinetics Sues Bristol-Myers Squibb Over MYQORZO Patent
CYTK has more than doubled off its 52-week low of $33.17.
Summary
Cytokinetics filed a lawsuit against Bristol-Myers Squibb and MyoKardia seeking a declaration that MYQORZO does not infringe a BMS patent and that the patent is invalid.
Key Events · Legal and Risk Events · CYTK
-
Patent Litigation Initiated
A declaratory judgment complaint has been filed by Cytokinetics against Bristol-Myers Squibb and MyoKardia in the District of Delaware regarding U.S. Patent No. 12,616,697.
-
Non-Infringement and Invalidity Claims
The complaint seeks a judgment that Cytokinetics does not infringe the '697 patent and that the patent's claims are invalid.
-
Injunction Against Infringement Threats
An injunction is requested by Cytokinetics to prevent the defendants from threatening or initiating infringement litigation against the company or its MYQORZO customers, distributors, and other parties.
-
Jury Trial and Attorneys' Fees
A jury trial is demanded by Cytokinetics, which also seeks an award of costs and reasonable attorneys' fees under 35 U.S.C. § 285, asserting the case is exceptional.
Analysis · CYTK · Life Sciences
A declaratory judgment action has been filed by Cytokinetics against Bristol-Myers Squibb and MyoKardia, seeking to establish that its commercial drug MYQORZO (aficamten) does not infringe U.S. Patent No. 12,616,697 and that the patent is invalid. This proactive legal move aims to clear the path for MYQORZO, which is central to the company's commercial future. The litigation directly targets a potential patent threat from a major competitor, and the outcome could affect Cytokinetics' ability to market MYQORZO without licensing fees or an injunction. The company is also seeking to enjoin the defendants from threatening infringement litigation against its customers and distributors, which would protect its commercial ecosystem. Given that MYQORZO is the company's lead product and has recently received regulatory approvals, this patent dispute is a significant legal risk that could impact the company's revenue trajectory.
At the time of this filing, CYTK was trading at $75.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.5B. The 52-week trading range was $33.17 to $88.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.